Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Lipcan

Gastroenterology Ansonia, CT Medical Doctor

NPI 1770624447 CMS profile 261595

22 Westfield Ave, Ansonia, CT 06401

Open in the dashboard

General payments

$6,642

359 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Lipcan of Ansonia, CT is reported in the CMS Open Payments database as having received $6,642 across 359 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $874 39
2022 General $2,059 101
2021 General $1,575 82
2020 General $414 24
2019 General $1,721 113

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Lipcan
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Michael Lipcan were reported at $874. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Michael Lipcan Gastroenterology median Middle half National median
2019 $1,721 $417 $126–$1,100 $163
2020 $414 $224 $74–$624 $114
2021 $1,575 $352 $106–$1,054 $132
2022 $2,059 $448 $129–$1,270 $149
2023 $0 $533 $150–$1,390 $160
2024 $0 $605 $160–$1,606 $164
2025 $874 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,334 77 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,144 63 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,056 51 payments
  4. Janssen Biotech, Inc. $519 29 payments
  5. Gilead Sciences, Inc. $460 34 payments
  6. Celgene Corporation $338 20 payments
  7. QOL Medical, LLC $309 10 payments
  8. Ferring Pharmaceuticals Inc. $140 7 payments
  9. Braintree Laboratories, Inc. $139 7 payments
  10. Ironwood Pharmaceuticals, Inc $139 7 payments
  11. Other $1,064 54 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,621 358 payments
  2. Consulting Fee $21 1 payment
Products named General payments · program years 2019–2025
  1. XIFAXAN $921 47 payments
  2. ENTYVIO Internal Medicine $581 23 payments
  3. LINZESS $513 34 payments
  4. STELARA $485 28 payments
  5. CREON $451 33 payments
  6. HUMIRA $450 24 payments
  7. ZEPOSIA $319 19 payments
  8. Sucraid $276 9 payments
  9. SIMPONI $251 16 payments
  10. Entyvio Lower GI $191 13 payments
  11. Other $3,020 165 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

791

Median for Gastroenterology: 569

Drug cost

$92,912

Median for Gastroenterology: $104,976

Branded share of claims

19.3%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sandostatin Lar Depot Octreotide Acetate,mi-Spheres Brand 12 $55,060
Zenpep Lipase/Protease/Amylase Brand 14 $17,213
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 109 $6,490
Omeprazole Generic 454 $6,325
Mesalamine Generic 19 $5,386
Pantoprazole Sodium Generic 139 $1,722
Famotidine Generic 14 $314
Nadolol Generic 12 $215
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 18 $188

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$182,240

Of which drugs: $139,815

Medicare patients

185

Average age 73

Services billed

8,504

101 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 34%
Diabetes 30%
Chronic kidney disease 25%
Depression 25%
Osteoporosis 21%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

359 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record